Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
21.83
-0.82 (-3.62%)
At close: Apr 28, 2026, 4:00 PM EDT
21.98
+0.15 (0.69%)
After-hours: Apr 28, 2026, 4:29 PM EDT

Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.

The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.

Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Pulse Biosciences, Inc.
Pulse Biosciences logo
Country United States
Founded 2014
IPO Date May 18, 2016
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 116
CEO Paul LaViolette

Contact Details

Address:
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
United States
Phone 510-906-4600
Website pulsebiosciences.com

Stock Details

Ticker Symbol PLSE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001625101
CUSIP Number 74587B101
ISIN Number US74587B1017
Employer ID 46-5696597
SIC Code 3841

Key Executives

Name Position
Darrin R. Uecker Chief Technology Officer and Director
Jon Skinner Chief Financial Officer
Liane Teplitsky Chief Operating Officer
Steven T. Weber Vice President of Accounting, Principal Accounting Officer and Global Corporate Controller
Kenneth B. Stratton Esq., J.D. General Counsel and Corporate Secretary
Patty Perla Vice President of Human Resources
David Danitz Senior Vice President of Engineering
Dr. Gansevoort Dunnington M.D. Chief Medical Officer
Dr. Niv Ad M.D. Chief Science Officer of Cardiac Surgery
Dr. David Kenigsberg FACC, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 27, 2026 8-K Current Report
Apr 16, 2026 8-K Current Report
Apr 9, 2026 8-K Current Report
Apr 7, 2026 8-K Current Report
Mar 27, 2026 8-K Current Report
Mar 17, 2026 8-K Current Report
Mar 12, 2026 8-K Current Report
Mar 9, 2026 8-K Current Report
Mar 3, 2026 8-K Current Report
Mar 2, 2026 8-K/A [Amend] Current report